 | Up a level |
Danieli, L; Roccatagliata, L; Distefano, D; Prodi, E; Riccitelli, G C; Diociasi, A; Carmisciano, L; Cianfoni, A; Bartalena, T; Kaelin-Lang, A; Gobbi, C; Zecca, C; Pravatà, E (2022). Nonlesional Sources of Contrast Enhancement on Postgadolinium "Black-Blood" 3D T1-SPACE Images in Patients with Multiple Sclerosis. AJNR. American journal of neuroradiology, 43(6), pp. 872-880. American Society of Neuroradiology 10.3174/ajnr.A7529
Sacco, R; Disanto, G; Maraffi, I; Candrian, U; Kamm, Christian Philipp; Rossi, S; Schwegler, G; Gallo, A; Gobbi, C; Zecca, C (2020). Infusion-related reactions during Natalizumab treatment: Do we still need a post-infusion observation period? Multiple Sclerosis and Related Disorders, 38, p. 101523. Elsevier 10.1016/j.msard.2019.101523
Achtnichts, L; Chan, A; Czaplinski, A; Derfuss, T; Du Pasquier, R; Findling, O; Gobbi, C; Hoepner, R; Kamber, N; Kamm, C P; Kuhle, J; Lalive, P; Lutterotti, A; Martin, R; Müller, S; Papadopoulou, A; Pot, C; Salmen, A; Schippling, S and Zecca, C (2019). Specific aspects of immunotherapy for multiple sclerosis in Switzerland: A structured commentary. Clinical and translational neuroscience, 3(1), 2514183X1882207. Sage Publications 10.1177/2514183X18822073
Cereda, Cw; Zecca, C; Mazzucchelli, L; Valci, L; Staedler, C; Bassetti, Cl; Gobbi, C (2013). Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy. Multiple sclerosis journal, 19(6), pp. 820-3. London: Sage 10.1177/1352458512461969
